top of page
Screen Shot 2022-09-27 at 9.27.44 pm.png

​Developing novel small molecules as a therapeutic for coronary artery inflammation and consequential disease

Screen Shot 2022-09-27 at 9.26.15 pm.png


Prokardia was founded by Professor Gemma Figtree - Head of the Australian Cardiovascular Alliance and Professor Michael Kassiou - Academic Director, The University of Sydney Drug Discovery Initiative.

Chronic low-grade inflammation contributes to the development of cardiovascular disease and the P2X7 receptor mediates inflammation and cellular death. Activation of P2X7R increases IL-1β and IL-18 which have been implicated in the development of many cardiovascular conditions including pulmonary hypertension and atherosclerosis.


Atherosclerosis: Plaque volume and characteristics in Apolipprotein E knockout mice...


Pulmonary hypertension: pulmonary and right ventricular fibrosis, as well as right ventricular ...



Professor in Medicine at the University of Sydney and interventional cardiologist at the...

bottom of page